Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 14;8:114. doi: 10.1038/s41420-022-00915-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — A Western blot showing the expression of GSDMD when knocking down ATF-4. B Western blot showing the expression of ATF4 when knocking down GSDMD. C–E After GSDMD siRNA, TG or GSDMD-overexpression treatment, qPCR was used to detect the change of mRNA level of GSDMD (C), ER-stress downstream genes GRP94 (D) and CHOP (E) in Cal-27 cells. F–H After GSDMD siRNA, TG or TG + siRNA treatment, qPCR was used to detect the change of mRNA level of GSDMD (F), ER-stress downstream genes GRP94 (G) and CHOP (H) in Cal-27 GSDMD stable overexpression cells. (I) Flow cytometry to detect cell death after treatment with cisplatin (48 h), in control cells, GSDMD-overexpression cells and GSDMD-overexpression cells with PERK-inhibitor (GSK2606414, 1 μM, 48 h) treatment. (J). The results of statistical analysis of (I).